Free Trial

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company logo
$228.12 +1.17 (+0.52%)
(As of 05:30 PM ET)

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
6

Based on 6 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for BDX.

Consensus Price Target

$283.50
24.28% Upside
According to the 6 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $283.50. The highest price target for BDX is $312.00, while the lowest price target for BDX is $270.00. The average price target represents a forecasted upside of 24.28% from the current price of $228.12.
Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

Sign Up

BDX Analyst Ratings Over Time

TypeCurrent Forecast
12/27/23 to 12/26/24
1 Month Ago
11/27/23 to 11/26/24
3 Months Ago
9/28/23 to 9/27/24
1 Year Ago
12/27/22 to 12/27/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$283.50$283.00$279.50$279.57
Forecasted Upside24.28% Upside26.23% Upside15.75% Upside15.29% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Becton, Dickinson and Company Stock vs. The Competition

TypeBecton, Dickinson and CompanyMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside24.92% Upside26,221.54% Upside13.49% Upside
News Sentiment Rating
Neutral News

See Recent BDX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/1/2024Evercore ISI
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$286.00 ➝ $290.00+20.29%
10/1/2024Citigroup
3 of 5 stars
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$255.00 ➝ $275.00+14.08%
8/2/2024Raymond James
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$275.00 ➝ $270.00+12.55%
7/26/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$270.00 ➝ $280.00+17.80%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$274.00+21.82%
5/6/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$305.00 ➝ $312.00+31.85%
12/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$310.00 ➝ $280.00+17.52%
11/10/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$305.00 ➝ $280.00+19.33%
1/3/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$250.00 ➝ $290.00+14.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:49 PM ET.


Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 18, 2024. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

  • Recent institutional interest has surged, with Neo Ivy Capital Management acquiring 7,010 shares valued at approximately $1,690,000, indicating strong confidence in the company's future performance.
  • The stock has received positive ratings from multiple analysts, with an average rating of "Buy" and a price target of $283.50, suggesting potential for price appreciation.
  • Becton, Dickinson and Company reported a strong quarterly earnings performance, with an EPS of $3.81, exceeding analyst expectations, which reflects robust operational efficiency and profitability.
  • The current stock price is $219.16, which is near its 12-month low of $218.75, potentially offering a buying opportunity for investors looking for value.
  • Institutional investors own 86.97% of the company's stock, which often indicates stability and confidence in the company's long-term prospects.

Becton, Dickinson and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

  • The stock has recently experienced a decline, trading down 1.0% to $219.16, which may signal weakness in market sentiment.
  • Despite strong earnings, the company has a relatively high P/E ratio of 37.28, which could indicate that the stock is overvalued compared to its earnings.
  • There has been a reduction in holdings by some institutional investors, such as Orion Portfolio Solutions LLC, which decreased its position by 17.9%, potentially reflecting concerns about future performance.
  • The company has a debt-to-equity ratio of 0.69, which, while not excessively high, suggests that it is somewhat reliant on debt financing, posing risks in a rising interest rate environment.
  • Market volatility and economic uncertainties could impact the healthcare sector, including Becton, Dickinson and Company, leading to potential fluctuations in stock performance.

BDX Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $283.50, with a high forecast of $312.00 and a low forecast of $270.00.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BDX shares.

According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 24.28% based on their 12-month stock forecasts.

Over the previous 90 days, Becton, Dickinson and Company's stock had 1 upgrade by analysts.

Becton, Dickinson and Company has been rated by research analysts at Citigroup, and Evercore ISI in the past 90 days.

Analysts like Becton, Dickinson and Company more than other "medical" companies. The consensus rating for Becton, Dickinson and Company is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BDX compares to other companies.


This page (NYSE:BDX) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners